证券代码：688382 证券简称：益方生物 公告编号：2026-007 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 召开日期时间：2026 年 2 月 26 日 10 点 00 分 召开地点：上海市浦东新区张衡路 1000 弄 63 号 （五） 网络投票的系统、起止日期和投票时间。 益方生物科技（上海）股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 26 日 至2026 年 2 月 26 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 股东会召开日期：2026年2月26日 ...

证券代码：688382 证券简称：益方生物 公告编号：2026-006 益方生物科技（上海）股份有限公司 第二届董事会 2026 年第一次会议决议公告 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）及 指定媒体的《益方生物科技（上海）股份有限公司关于调整部分募集资金投资 项目内部投资结构的公告》（公告编号：2026-005）。 表决结果：同意 9 票；反对 0 票；弃权 0 票。 本议案尚需提交公司股东会审议。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 益方生物科技（上海）股份有限公司（以下简称"公司"）第二届董事会 2026 年第一次会议（以下简称"本次会议"）于 2026 年 2 月 10 日在公司会议室 以现场及通讯表决方式召开，本次会议通知已于 2026 年 2 月 5 日通过书面方式 送达全体董事。本次会议由董事长 Yaolin Wang（王耀林）先生召集并主持，会 议应出席董事 9 人，实际出席董事 9 人，公司高级管理人员列席本次会议。本 次会议的召 ...

Core Viewpoint - The A-share market is experiencing a strong upward trend, particularly in the innovative drug sector, with significant gains in the ChiNext Innovative Drug ETF [1][3]. Group 1: Market Performance - As of 11:08 on February 10, the ChiNext Innovative Drug ETF (589120) surged by 2%, marking a potential two-day consecutive rise [1]. - Major component stocks of the ETF, such as Rongchang Biopharma and Baili Tianheng, saw increases exceeding 5%, while others like Baijie Shenzhou rose over 4% [3]. Group 2: Key Component Stocks - The top ten component stocks of the ChiNext Innovative Drug ETF include: - J-Z**KD with a 4.04% increase and an estimated weight of 10.43% - Baili Tianheng with a 5.10% increase and an estimated weight of 7.89% - Rongchang Biopharma with a 5.51% increase and an estimated weight of 6.35% [4]. Group 3: Industry Developments - Innovent Biologics announced the approval of its ICP-538, a VAV1 molecular glue degrader, for clinical research, marking it as the first of its kind in China and the second globally [4]. - Baili Tianheng's recent shareholder meeting approved significant resolutions, including the issuance of debt financing tools and extending the validity of H-share issuance [5]. Group 4: Strategic Collaborations - Innovent Biologics entered a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, receiving an upfront payment of $350 million and potential milestone payments totaling up to $8.5 billion [5]. Group 5: Industry Growth and Trends - The Chinese innovative drug sector is transitioning from "pipeline expectations" to "performance realization," with over 70% of companies projected to achieve revenue growth by 2025 [8]. - The total value of License-out transactions for Chinese innovative drugs skyrocketed from $2.562 billion in 2017 to an estimated $140.274 billion by 2025, indicating a significant increase in global recognition [6]. Group 6: Investment Opportunities - Three key investment themes for 2026 in the innovative drug sector include: 1. Accelerated BD (Business Development) overseas, focusing on ADC, dual antibodies, and GLP-1RA [9]. 2. Policy support for innovative drug development, enhancing commercialization opportunities [9]. 3. Monitoring critical clinical data and commercialization milestones for new drugs [10].

2月9日，A股市场震荡上行，沪指强势涨超1%，AI主线持续火热！截至15:00，科创人工智能ETF汇添富(589560)收涨4.44%，终结三连阴。资金持续涌 入AI主题，科创人工智能ETF汇添富(589560)近5个交易日内有3日资金净流入，合计"吸金"1263.02万元。其联接基金（A: 026654，C: 026655）上周已 经募集结束，成立在即，场外投资者后续可重点关注！ 科创人工智能ETF汇添富(589560)标的指数成分股多数冲高，成分股芯原股份涨超14%，复旦微电涨超9%，澜起科技涨超6%，云天励飞涨超5%，寒武 纪涨超4%，金山办公、中科星图等跟涨。 | 序号 | 代码 | 名称 | 申万―级行业 | 涨跌幅 | 估算权重 ▼ | | --- | --- | --- | --- | --- | --- | | 1 | 688521 | 芯原胎份 | 电子 | 14.87% | 12.05% | | 2 | 688008 | 淘起科技 | 电子 | 6.06% | 12.04% | | 3 | 688111 | 金山办公 | 计算机 | 1.12% | 9.01% | | 4 | ୧୫୫೭୧୧ ...

Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical sector, including Innovent Biologics, Efang Biologics, Tianshili, WuXi AppTec, and Mindray Medical [4][28]. Core Insights - The policy-driven upgrade of traditional Chinese medicine (TCM) industry is expected to enhance industry concentration in the medium to long term, benefiting companies with strong quality control and innovative capabilities [2][24]. - The implementation plan for high-quality development of the TCM industry aims to establish a collaborative development system by 2030, focusing on raw material supply, innovation, production quality control, and internationalization [2][23]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, recommending a focus on innovative drugs and high-end medical devices [3][26]. Summary by Sections Market Review - The A-share pharmaceutical index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [1][16]. - The Hong Kong Hang Seng Medical Health Index fell by 1.41%, but still outperformed the Hang Seng Index by 1.65 percentage points [1][16]. Policy Insights - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the TCM industry, which includes fostering leading enterprises and establishing high-standard raw material production bases [2][24]. - The plan emphasizes digitalization and sustainability, aiming to raise compliance standards and accelerate the exit of smaller companies from the market [2][25]. Company Updates - Recent clinical progress includes the NDA submission for HRS-9531 by Heng Rui Medicine and the initiation of clinical trials for various drugs by other companies [1][31][32]. - Key companies such as Yunnan Baiyao, Baiyunshan, and Taiji Group are highlighted for their strong positions in raw material supply [2][25]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Innovent Biologics projected to have an EPS of 0.49 in 2025 and WuXi AppTec expected to reach an EPS of 5.07 in the same year [4][28]. - The pharmaceutical manufacturing industry reported a revenue decline of 1.2% year-on-year for 2025, with total revenue reaching 2,487 billion yuan [51].

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for four companies, including Yifang Biotechnology, which is required to clarify compliance operations related to safety production [1] - Yifang Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities acting as its sole sponsor [1] - The CSRC has requested Yifang Biotechnology to provide legal opinions on several matters, including the company's business scope and compliance with foreign investment policies [1] Group 2 - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products and several products in various clinical stages [2] - The commercialized products include BPI-D0316 and D1553, while core clinical products include D-2570 and D-0502 [2] - The pipeline also features a clinical candidate product, D-0120, and three preclinical candidates: YF087, YF550, and YF057 [2]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for four companies, including Yifang Biotechnology, which is required to clarify compliance operations related to safety production [1] - Yifang Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The CSRC has requested Yifang Biotechnology to provide legal opinions regarding its business scope and whether it involves restricted foreign investment areas, as well as compliance with foreign investment policies [1] Group 2 - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (Befotizumab and Gexorase), two core products in clinical stages (D-2570 and Terysqun), one clinical candidate (Dabinoside), and three preclinical candidates (YF087, YF550, and YF057) [2]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for four companies, including Yifang Biotechnology, which is required to clarify compliance operations related to safety production [1] - Yifang Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The CSRC requests Yifang Biotechnology to provide legal opinions regarding its business scope and whether it involves areas restricted for foreign investment, as well as compliance with foreign investment access policies [1] Group 2 - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (Befotizumab and Gexorase), two core products in clinical stages (D-2570 and Terysqun), one clinical candidate (Dabinoside), and three preclinical candidates (YF087, YF550, and YF057) [2]

益方生物科技（上海）股份有限公司 ■ （一）业绩预告期间 2025年1月1日至2025年12月31日。 经财务部门初步测算，公司预计2025年度实现利润总额-29,182.21万元，预计实现归属于母公司所有者 的净利润-29,219.53万元，归属于母公司所有者扣除非经常性损益后的净利润为-30,440.75万元。 （三）公司本次业绩预告相关财务数据未经注册会计师审计。 二、上年同期业绩情况 2025年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 （二）业绩预告情况 一、本期业绩预告情况 公司预计2025年实现营业收入3,724.52万元，扣除与主营业务无关的业务收入和不具备商业实质的收入 后的营业收入为3,724.52万元，低于1亿元。 四、风险提示 本次业绩预告是公司财务部门基于年度经营情况和自身判断进行的初步核算，尚未经注册会计师审计。 截至本公告披露日，公司不存在可能影响本次业绩预告内容准确性的重大不确定因素。 五、其他说明事项 以上预告数据仅为初步核算数据，具体准确的财务数据以公司正式披露的经 ...

2025年度，公司业绩变化主要受到研发投入强度与营收构成的共同影响。随着研发管线的扎实推进，多 个核心临床项目已进入关键阶段，并取得积极进展，研发投入维持在较高水平：口服选择性雌激素受体 降解剂(SERD)D0502正在国内开展二线治疗注册III期临床试验;TYK2抑制剂D-2570已启动多个自身免疫 性疾病领域的临床探索，包括正在国内开展的溃疡性结肠炎II期临床试验、银屑病注册III期临床试验， 以及在美国开展的I期临床试验等;URAT1抑制剂D-0120在美国开展的联合用药II期临床试验于报告期内 完成随访，预计将于2026年第一季度完成全部研究工作。 益方生物(688382.SH)发布2025年年度业绩预亏公告，预计2025年度实现归属于母公司所有者净亏损2.92 亿元。 2025年，公司临床前管线转化也取得关键进展，两款具有创新性的临床前候选药物，WRN抑制剂 YF087和KIF18A抑制剂YF550在多项临床前研究中展现出优秀的抗肿瘤潜力，目前正在开展IND支持性 研究，为后续进入临床阶段做准备;与此同时，公司持续投入早期研发，包括其他候选药物的开发、创 新技术平台建设以及药物的早期发现，为长期发展 ...